COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01649700
Recruitment Status : Completed
First Posted : July 25, 2012
Last Update Posted : September 12, 2014
Information provided by (Responsible Party):
Oscar Kuang-Sheng Lee, National Yang Ming University

Brief Summary:
The study is to investigate the efficacy and safety of autologous transplantation of adipose-derived mesenchymal stem cells in patients with the sequelae caused by severe brain injury.

Condition or disease Intervention/treatment Phase
The Sequelae Caused by Severe Brain Injury Biological: autologous adipose-derived mesenchymal stem cells Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells
Study Start Date : October 2011
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2013

Arm Intervention/treatment
Experimental: Mesenchymal stem cells treatment
All subjects will receive autologous adipose-derived mesenchymal stem cells
Biological: autologous adipose-derived mesenchymal stem cells
Patients will receive five infusions, one month apart, each comprising 5-7x10^7 cells of autologous adipose-derived mesenchymal stem cells.

Primary Outcome Measures :
  1. Safety evaluation [ Time Frame: 16 months ]
    Safety evaluate through vital signs, the results of clinical lab tests and adverse events (AEs).

Secondary Outcome Measures :
  1. Positron emission tomography [ Time Frame: 13 months ]
    18F-FDG used for the assessment of glucose metabolism in the brain

  2. Magnetic Resonance Imaging [ Time Frame: 16 months ]
    changes in the volume of brain lesions

  3. Electroencephalogram [ Time Frame: 16 months ]
    improvement of continuous slow-waves and irritative features

  4. Neuropsychological assessment [ Time Frame: 16 months ]
  5. Electrodiagnostic Testing [ Time Frame: 16 months ]
    improvement of subjects' sensory neurologic pathways

  6. Assessment of language and swallowing functions [ Time Frame: 16 months ]
    changes in levels of severity: normal/slight/mild/moderate/severe

  7. Measure of the severity of disability [ Time Frame: 16 months ]
  8. Assessment of spasticity and strength [ Time Frame: 16 months ]
  9. Assessment of brain motor control [ Time Frame: 16 months ]
    measurement of the electrical activities in the muscles during specific testing procedures

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has a confirmed diagnosis of a brain AVM (arteriovenous malformation).
  • Stroke-like symptoms, including paralysis, caused by brain AVM hemorrhage.
  • Subject's modified Rankin scale (mRS) grades IV~V.
  • Ages between 20~40 years.
  • Estimated life expectancy must be greater than 2 months.
  • Signed informed consent from the subject.

Exclusion Criteria:

  • Pregnancy test positive.
  • Subject infected with hepatitis C, HIV or syphilis.
  • Subject not suitable for liposuction surgery.
  • Subject not eligible for PET or MRI.
  • Subject enrolled in any other cell therapy studies within the past 30 days.
  • Subject deemed to be not suitable for the study by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01649700

Layout table for location information
Taipei Veterans General Hospital
Taipei, Taiwan
Sponsors and Collaborators
National Yang Ming University
Layout table for additonal information
Responsible Party: Oscar Kuang-Sheng Lee, Director of Stem Cell Research Centre, National Yang Ming University Identifier: NCT01649700    
Other Study ID Numbers: SB-VGH-201101
First Posted: July 25, 2012    Key Record Dates
Last Update Posted: September 12, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Injuries
Wounds and Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System